PVAM
SRPT icon

Pacific View Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Pacific View Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,421
Closed -$290K – 53
2019
Q1 		$290K Sell
2,421
-99
-4% -$12.7K 0.3% 50
2018
Q4 		$276K Hold
2,520
– – 0.32% 49
2018
Q3 		$406K Sell
2,520
-65
-3% -$8.89K 0.32% 70
2018
Q2 		$341K Sell
2,585
-241
-9% -$22.7K 0.27% 81
2018
Q1 		$209K Sell
2,826
-7,445
-72% -$496K 0.16% 107
2017
Q4 		$581K Buy
+10,271
New +$544K 0.39% 70

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacific View Asset Management's SRPT Position: Q2 2019 in Review

Pacific View Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 2,421 shares — an estimated $290K sold.

Pacific View Asset Management first reported a position in SRPT in Q4 2017 and held it in 6 quarters. The position peaked at $581K in Q4 2017. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Pacific View Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pacific View Asset Management sold 2,421 Sarepta Therapeutics shares in Q2 2019, an estimated $290K.
  • Pacific View Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 6 quarters.
  • Pacific View Asset Management's Sarepta Therapeutics position peaked at $581K in Q4 2017.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Pacific View Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.